International Journal of Nanomedicine · 2020 · 33 citations · 24 references
PharmacyPharmaceuticsPharmacologyDrug DeliveryNanoparticle Drug DeliveryTargeted Drug DeliveryBlood-brain Barrier DeliveryBlood-brain Barrier PenetrationCancer NanomedicineMetastatic Disease TreatmentNanocarriers For TherapeuticsNanomedicineBlood-brain Barrier PermeabilityDrug Co-deliveryDrug Delivery NanocarriersNanocarriersNon-small Cell Lung Cancer TherapyNon-small Cell Lung Cancer TreatmentSelf-assembling NanocarriersTargeted Delivery Across The Blood-brain Barrier
PURPOSE: Currently, the treatment of brain metastases from non-small cell lung cancer (NSCLC) is rather difficult in the clinic. A combination of small molecule-targeted drug and chemo-drug is a promising therapeutic strategy for the treatment of NSCLC brain metastases. But the efficacy of this combination therapy is not satisfactory due to the blood-brain barrier (BBB). Therefore, it is urgent to develop a drug delivery system to enhance the synergistic therapeutic effects of small molecule-targeted drug and chemo-drug for the treatment of NSCLC brain metastases. METHODS: T7 peptide installed and osimertinib (AZD9291) loaded intracellular glutathione (GSH) responsive doxorubicin prodrug self-assembly nanocarriers (T7-DSNPs/9291) have been developed as a targeted co-delivery system to enhance the combined therapeutic effect on brain metastases from NSCLC. In vitro cell experiments, including intracellular uptake assay, in vitro BBB transportation, and MTT assay were used to demonstrate the efficacy of T7-DSNPs/9291 in NSCLC brain metastasis in vitro. Real-time fluorescence imaging analysis, magnetic resonance imaging analysis, and Kaplan-Meier survival curves were used to study the effect of T7-DSNPs/9291 on an animal model in vivo. RESULTS: T7-DSNPs/9291 could significantly enhance BBB penetration of AZD9291 and doxorubicin via transferrin receptor-mediated transcytosis. Moreover, T7-DSNPs/9291 showed significant anti-NSCLC brain metastasis effect and prolonged median survival of an intracranial NSCLC brain metastasis animal model. CONCLUSION: T7-DSNPs/9291 is a potential drug delivery system for the combined therapy of brain metastasis from NSCLC.
24
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2018 · 17K citations · Full text
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
Tony Mok, Yi‐Long Wu, Myung‐Ju Ahn et al. · New England Journal of Medicine · 2016 · 3.3K citations · Full text
Medicine, Oncology, Pharmacology +16
Thanyanan Reungwetwattana, Kazuhiko Nakagawa, Byoung Chul Cho et al. · Journal of Clinical Oncology · 2018 · 789 citations · Full text
Medicine, Oncology, Pharmacology +17
Riccardo Soffietti, Martin Köcher, Ufuk Abacıoğlu et al. · Journal of Clinical Oncology · 2012 · 645 citations · Full text